EQS-News: Benzinga / Key word(s): Healthcare
Glucotrack Commences Transition From Concept To Reality With Breakthrough Clinical Trial
25.02.2025 / 14:58 CET/CEST
The issuer is solely responsible for the content of this announcement.
By JE Insights, Benzinga
DETROIT, MICHIGAN – February 25, 2025 (NEWMEDIAWIRE) – Glucotrack, Inc. (NASDAQ: GCTK) reports it has achieved a significant milestone in its mission to transform diabetes management through three distinct advances: direct blood glucose measurement, hassle-free monitoring and the first multi-year continuous glucose monitoring (CGM) system. The company announced the successful completion of its first human clinical trial for its Continuous Blood Glucose Monitor (CBGM), a device that could eliminate both the accuracy limitations of current glucose monitors and the burden of frequent sensor changes.
Unlike existing continuous glucose monitors that measure interstitial fluid and require sensor replacement every 10 to 15 days, GlucoTrack says its CBGM represents a radical shift in diabetes care
Dieser Beitrag wurde original veröffentlicht auf: link zum Beitrag
